Provided by Tiger Fintech (Singapore) Pte. Ltd.

Zura Bio

1.28
+0.200018.52%
Post-market: 1.300.0200+1.56%18:28 EDT
Volume:389.07K
Turnover:473.73K
Market Cap:83.58M
PE:-1.93
High:1.28
Open:1.10
Low:1.10
Close:1.08
Loading ...

Zura Bio’s Growth Potential: Buy Rating Backed by Key Catalysts and Phase 2 Developments

TIPRANKS
·
07 Mar

Zura Bio to Participate in Global Healthcare Conference

TIPRANKS
·
24 Feb

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

Business Wire
·
24 Feb

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

Simply Wall St.
·
22 Jan

Reversal Of Fortune For Zura Bio Insiders Who Made A US$1.01m Purchase

Simply Wall St.
·
27 Dec 2024

Analysts Offer Insights on Healthcare Companies: 60 Degrees Pharmaceuticals, Inc. (SXTP), Ionis Pharmaceuticals (IONS) and Zura Bio (ZURA)

TIPRANKS
·
25 Dec 2024

Zura Bio Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow Jones
·
24 Dec 2024

Cautious Hold Rating on Zura Bio Due to Efficacy Concerns and Competitive Risks

TIPRANKS
·
24 Dec 2024

Zura Bio Begins Phase 2 Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

MT Newswires Live
·
23 Dec 2024

Zura Bio Initiates Global Phase 2 TibuSURE Study

TIPRANKS
·
23 Dec 2024

Zura Bio launches global Phase 2 TibuSURE study evaluating tibulizumab

TIPRANKS
·
23 Dec 2024

Zura Bio Launches Global Phase 2 Tibusure Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

THOMSON REUTERS
·
23 Dec 2024

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

Business Wire
·
23 Dec 2024

Positive Buy Rating for Zura Bio Driven by Promising Tibulizumab Data and IL-17/BAFF Hypotheses Support

TIPRANKS
·
21 Dec 2024

Zura Bio Ltd : Leerink Partners Cuts Target Price to $12 From $15

THOMSON REUTERS
·
11 Dec 2024

Zura Bio to Present at Healthcare Conference

TIPRANKS
·
25 Nov 2024